ArticleCureus2026
Tabes Dorsalis With Spinal Meningeal Involvement and Possible Concomitant Epstein-Barr Virus Reactivation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report an exceptionally rare case of tabes dorsalis with concomitant hypertrophic spinal pachymeningitis and incidental qualitative detection of Epstein-Barr virus (EBV) DNA in the cerebrospinal fluid (CSF), highlighting the diagnostic challenges and potential systemic complications of late neurosyphilis. A 44-year-old immunocompetent man presented with a two-year history of progressive sensory ataxia. Thoracic spine magnetic resonance imaging demonstrated longitudinal posterior column T2 hyperintensity with diffuse dural thickening and enhancement. Initial multiplex polymerase chain reaction of the CSF detected EBV DNA, raising concern for viral myelitis and prompting consideration of antiviral therapy. However, serological testing confirmed syphilis (rapid plasma reagin (RPR) 1:16; Treponema pallidum hemagglutination assay (TPHA) 1:20,480), while HIV and Human T-lymphotropic virus-1 (HTLV-1) testing were negative. Although CSF-Venereal Disease Research Laboratory (VDRL) was unavailable, the diagnosis was revised to probable neurosyphilitic myelopathy with tabetic features based on the clinical presentation, serological findings, CSF profile, and characteristic neuroimaging abnormalities. Intravenous ceftriaxone was initiated, resulting in clinical improvement, reduced CSF pleocytosis, and clearance of EBV DNA on follow-up analysis, suggesting incidental viral reactivation rather than active EBV infection. The patient was discharged in stable neurological condition but died suddenly within 24 hours. Although the exact cause of death could not be established, a cardiovascular complication of late-stage syphilis was considered the most likely explanation. This case broadens the recognized imaging spectrum of neurosyphilis by demonstrating hypertrophic spinal pachymeningitis with incidental EBV DNA detection and highlights the importance of considering syphilis in patients with posterior column myelopathy. It also emphasizes the need for comprehensive cardiovascular assessment in patients with late-stage syphilis to identify potentially life-threatening systemic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.